Antitumor agents. 44. Bis(helenalinyl) esters and related derivatives as novel potent antileukemic agents. 1981

K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim

Bis(helenalinyl), bis(plenolinyl), bis(2,3-dihydrohelenalinyl), and bis(2,3,11,13-tetrahydrohelenalinyl) esters have been synthesized in an effort to elucidate the role of the two enone alkylating centers, beta-unsubstituted cyclopentenone and alpha-methylene gamma-lactone, as well as the significance of the diester linkage with respect to the enhanced in vivo P-388 lymphocytic leukemia antileukemic activity of bis(helenalinyl) malonate (2) against P-388 lymphocytic leukemia in the mouse. The bisesters (2-5; 7, 8; 10, 11) are, in general, more potent and less toxic than their corresponding parent alcohols (1, 6; 9; 14). The beta-unsubstituted cyclopentenone ring and the alpha-methylene gamma-lactone moiety in the bisesters play important roles for the enhancement of the P-388 antileukemic activity. Removal of the enone double bonds in both alkylating centers of 2 gave rise to inactive compounds. Except for 2, the potent antileukemic activity of the bis(helenalinyl) esters (3-5) appears to be independent of the ester chain length.

UI MeSH Term Description Entries
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D012717 Sesquiterpenes Fifteen-carbon compounds formed from three isoprenoid units with general formula C15H24. Farnesanes,Farnesene,Farnesenes,Sesquiterpene,Sesquiterpene Derivatives,Sesquiterpenoid,Sesquiterpenoids,Derivatives, Sesquiterpene
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
March 1982, Journal of pharmaceutical sciences,
K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
February 1994, Bioorganic & medicinal chemistry,
K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
June 2022, Molecules (Basel, Switzerland),
K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
January 2018, European journal of medicinal chemistry,
K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
November 2023, ACS medicinal chemistry letters,
K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
May 2013, Archives of pharmacal research,
K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
July 2022, Bioorganic & medicinal chemistry,
K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
September 2013, Journal of Asian natural products research,
K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
July 2013, Bioorganic & medicinal chemistry,
K H Lee, and T Ibuka, and D Sims, and O Muraoka, and H Kiyokawa, and I H Hall, and H L Kim
June 2006, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!